1-[3-[[(2,5-Dioxopyrrolidinyl)Oxy]Carbonyl]Phenyl]-1H-Pyrrole-2,5-Dione

1-[3-[[(2,5-Dioxopyrrolidinyl)Oxy]Carbonyl]Phenyl]-1H-Pyrrole-2,5-Dione, systematically designated as succinimidyl 3-maleimidobenzoate and commercially referenced as MBS, is a heterobifunctional crosslinker engineered for sequential conjugation of amine- and sulfhydryl-containing biomolecules. The compound presents a maleimide ring at the N-phenyl terminus and an NHS-activated ester at the meta-carboxyl position, with the rigid phenyl spacer delivering a through-bond distance of approximately 6.8 Å between reactive centers. A molecular weight of 314.25 g·mol⁻¹ (C₁₅H₁₀N₂O₆, CAS 58626-38-3) and a melting point of 170–172 °C are documented for the crystalline solid. Commercial specifications routinely require purity ≥95 % by reversed-phase HPLC (C18 column, acetonitrile/water gradient with 0.1 % TFA, UV detection at 254 nm). The material is hydrophobic; dissolution in anhydrous DMSO or DMF at 10–50 mM is standard for bioconjugation workflows, while aqueous solubility is negligible. Storage under argon at −20 °C in sealed, desiccated containers preserves the NHS ester and maleimide functionalities, each susceptible to nucleophilic hydrolysis. When integrated into a stepwise strategy—amine acylation first, followed by thiol addition to the maleimide—MBS enables precise architecture in protein-protein crosslinking, surface functionalization, and antibody-drug conjugate (ADC) construction, providing a well-characterized spacer that balances hydrophobic character with kinetic selectivity.

Physical and Chemical Identity Metrics

In solid-phase protein immobilization on NHS-activated agarose matrices, MBS is first coupled to amine-derivatized supports under anhydrous conditions to install surface maleimide groups. A 10‑ to 50‑fold molar excess of MBS in dry DMF is circulated through a packed bed (e.g., HiTrap NHS-activated HP columns on an ÄKTA pure system) for 1 h at 25 °C, followed by a rinsing cascade of anhydrous DMF and ice-cold 0.1 M sodium acetate, pH 5.0, to quench residual NHS esters without opening the maleimide ring. Subsequent incubation with a thiolated ligand (typical concentration 1–10 mg·mL⁻¹ in 50 mM HEPES, 5 mM EDTA, pH 6.8) for 4–16 h at 4 °C exploits the maleimide’s near‑quantitative thiol selectivity at this pH window. Excess free maleimide sites are capped with 1 mM 2‑mercaptoethanol. The efficiency of surface maleimide incorporation is monitored by reacting a resin aliquot with a fluorescent thiol probe, quantifying unquenched capacity with a fluorescence plate reader (ex 488 nm, em 520 nm) calibrated against a standard curve of a maleimide-bearing control resin. Residual MBS in the eluate must be verified below 0.1 μM by HPLC to prevent subsequent cross-reactivity in sensitive biological assays.

What Governs Maleimide Hydrolysis Rates Under Bioconjugation Conditions?

The dual reactivity of MBS imposes narrow operational pH and time boundaries, as both the NHS ester and the maleimide ring compete with water for nucleophiles. Published kinetic data for structurally analogous N‑arylmaleimides indicate that the maleimide ring undergoes base‑catalyzed hydrolysis to maleamic acid with a half‑life of approximately 11 h at pH 8.0 and 25 °C, while the same ring remains >90 % intact after 24 h at pH 6.5. This sharp threshold means that conjugation protocols must operate at pH ≤7.0 during the thiol‑addition step to preserve maleimide fidelity; a drift of merely 0.5 pH units upward can shorten the functional half‑life to 4 h or less. Concurrently, the NHS ester hydrolyzes in aqueous buffer with typical half‑lives of 4–6 h at pH 7.0 and 25 °C, requiring that the amine‑acylation step be completed within 2 h of dissolving the crosslinker. Tris, glycine, and other primary‑amine‑containing buffers must be strictly avoided during maleimide‑functionalization stages; their inadvertent presence leads to immediate NHS ester quenching and formation of unreactive amide by‑products, a failure mode frequently observed when automated liquid handlers aspirate from reservoirs that were inadequately flushed after a protein‑quenching step. For solid‑state storage, pre‑drying the crystalline powder under high vacuum (≤0.1 mbar) for 12 h is mandated if the container has been opened at ambient relative humidity ≥40 %, as surface‑adsorbed water catalyzes both NHS ester and maleimide degradation even at sub‑zero temperatures.

Automated conjugation protocols on Hamilton STAR and TECAN Freedom EVO platforms execute MBS‑mediated crosslinking in 96‑well formats with positive‑displacement pipetting to counteract the high vapour pressure of DMSO. A 10 mM stock solution in anhydrous DMSO is dispensed from septum‑capped glass vials; the vial headspace is backfilled with dry nitrogen after each access. In‑process HPLC checks with a Phenomenex Luna C18(2) column (5 μm, 150 × 4.6 mm) and a gradient of 10–90 % acetonitrile over 15 min have shown that NHS ester integrity in such stock solutions declines to 85 % of initial after 6 h at 22 °C in tightly sealed vessels; therefore, single‑use aliquots or a maximum stock shelf‑life of 24 h at 4 °C is enforced. DMSO‑induced needle clogging on the Hamilton STAR is mitigated by incorporating a 2‑μL air gap after aspiration and a high‑speed (50 μL·s⁻¹) dispense step. The conjugation sequence first mixes the amine‑containing biomolecule with a 5‑ to 20‑fold molar excess of MBS for 1 h at 25 °C in 50 mM phosphate, 150 mM NaCl, pH 7.2; excess crosslinker is removed via spin‑column (Zeba, 7 kDa MWCO) pre‑equilibrated with 50 mM citrate‑phosphate, pH 6.5. The subsequent thiol‑coupling phase proceeds for 16 h at 4 °C under argon, maintaining pH at 6.5–6.8 to suppress maleimide ring opening. This workflow, validated by SEC‑MALS (Wyatt Dawn Heleos II coupled with an Agilent 1260 HPLC), routinely yields conjugates with aggregate content below the 5 % limit prescribed in ICH Q6B for therapeutic conjugates.

Influence of Spacer Rigidity on Antibody‑Drug Conjugate Polydispersity

The planar aromatic spacer of MBS constrains rotational degrees of freedom more than the flexible aliphatic chains of EMCS or the cyclohexane ring of SMCC. When MBS is used to link a maytansinoid payload to lysine residues on a monoclonal antibody, the resulting drug‑to‑antibody ratio (DAR) distribution, determined by hydrophobic interaction chromatography (HIC, TSKgel Butyl‑NPR column with a gradient of 1.5–0 M ammonium sulfate), often exhibits a narrower DAR envelope than SMCC‑mediated conjugates due to the reduced probability of random‑coil conformations that can bury reactive thiols. However, the phenyl group introduces a hydrophobic patch that, in ADCs with DAR ≥ 5, can elevate dynamic light scattering (DLS)‑derived Z‑average diameters by 3–5 nm relative to sulfo‑MBS‑based conjugates, indicating a modest increase in inter‑ADC oligomerization under accelerated stress (40 °C, 75 % RH for 14 d as per ICH Q1B). This behavior contrasts with SMCC, where a more rigid cyclohexane spacer often yields higher‑order aggregates above 12 % total aggregate by SEC after identical stress, measured on a TSKgel G3000SWXL column. The property divergence makes MBS a candidate for applications in which the payload requires a defined aromatic π‑stacking environment for retention of cytotoxicity, provided that formulation buffers include 0.01–0.05 % polysorbate‑20 to mitigate inter‑particle hydrophobic interactions.

Crosslinker performance diverges markedly when comparing heterobifunctional architectures across membrane‑permeability requirements, spacer hydrophobicity, and reaction solvent constraints. While sulfo‑MBS (sulfo‑succinimidyl 3‑maleimidobenzoate) substitutes a sulfonate group to impart water solubility, it cannot traverse cell membranes, making MBS the reagent of choice for intracellular crosslinking in live‑cell protein interaction studies. The following comparative matrix summarizes key differentiators against common alternatives.

Residual moisture in DMSO stock solutions accelerates MBS inactivation through parallel hydrolysis pathways; Karl Fischer titration of DMSO drawn from a septum‑sealed bottle that has been repeatedly opened can show 0.5–1.0 % (w/v) water after a single day of use in a standard laboratory. At that water content, the NHS ester hydrolysis rate constant increases by roughly 2‑fold (empirical observation in an LC‑MS kinetic study, C18 column as above), demanding that crosslinker stocks be prepared fresh from a sealed desiccated vial for each run. The maleimide ring additionally exhibits susceptibility to reducing agents: TCEP and DTT, if carried into the thiol‑addition step at concentrations exceeding 0.1 mM, can reduce the maleimide double bond to succinimide, extinguishing thiol reactivity. For protocols employing TCEP‑mediated reduction of interchain antibody disulfides, the reducer must be buffer‑exchanged to below 10 μM before introducing MBS, verified by Ellman’s assay using 5,5′‑dithiobis(2‑nitrobenzoic acid) and a 412 nm absorbance calibration. Processing tolerance to amine nucleophiles is equally narrow: any carryover of ammonium ions (≥5 mM) from protein precipitation steps will irreversibly consume the NHS ester, lowering the effective conjugation yield to ≤30 % of the theoretical DAR, a threshold observed in scaling from 1‑L stirred‑tank to GMP‑compliant 50‑L single‑use bioreactor harvests where residual quench agents are incompletely cleared by tangential‑flow filtration (Pall Centramate, 30 kDa Pall Omega membrane).